[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vivax-malaria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vivax-malaria":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,62],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100597615",false,"NCT07060794","Tafenoquine and ACTs (TADORE- Plus)","TADORE+","Inclusion Criteria:\n\n* P. vivax peripheral parasitaemia (mono-infection)\n* G6PD normal status (G6PD activity ≥70% of the adjusted male median\n* as determined by the Standard G6PD (SD Biosensor, ROK))\n* Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n* Age ≥18 years\n* Haemoglobin at presentation ≥8g\u002Fdl\n* Written informed consent.\n* Living in the study area and willing to be followed for six months\n\nExclusion Criteria:\n\n* Danger signs or symptoms of severe malaria\n* Pregnant or lactating females\n* Regular use of drugs with haemolytic potential\n* Known hypersensitivity to any of the study drugs\n* History of any psychiatric disorder","ALL","18 Years",{"count":18,"type":19},507,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).",[25],"Vivax Malaria","NOT_YET_RECRUITING","2026-03-16",{"date":29,"type":30},"2026-03-18","ACTUAL",{"date":32,"type":19},"2026-06",{"date":34,"type":19},"2028-06",{"name":36,"class":37},"Menzies School of Health Research","OTHER",{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":43,"targetDuration":4,"studyType":20,"phases":45,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100628966","NCT07468513","Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.","Inclusion Criteria:\n\n* • P. vivax peripheral parasitaemia (mono-infection)\n\n  * G6PD intermediate or deficient status (G6PD activity 30-\\\u003C70% or ≤30% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK))\n  * Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n  * Age ≥18 years\n  * Haemoglobin at presentation ≥8g\u002Fdl\n  * Written informed consent\n  * Living in the study area and willing to be followed for six months.\n\nExclusion Criteria:\n\n* • Danger signs or symptoms of severe malaria\n\n  * Pregnant or lactating females\n  * Regular use of drugs with haemolytic potential\n  * Known hypersensitivity to any of the study drugs.",{"count":44,"type":19},100,[22],"A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg\u002Fkg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\\\u003C30% activity)",[25,48],"G6PD Deficiency",[50,51],"Primaquine in G6PD deficiency","Vivax malaria in G6PD deficient patients","RECRUITING","2026-03-09",{"date":55,"type":30},"2026-03-12",{"date":57,"type":30},"2024-05-17",{"date":59,"type":19},"2028-12-31",{"name":36,"class":37},4,{"id":63,"slug":4,"hasResults":10,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":20,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":61},"100527517","NCT06148792","A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria","A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria - TAfenoquine DOsing REvised","TADORE","Inclusion Criteria:\n\n* P. vivax peripheral parasitaemia (mono-infection)\n* G6PD normal status (G6PD activity ≥70% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK))\n* Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n* Written informed consent\n* Living in the study area and willing to be followed for six months\n\nExclusion Criteria:\n\n* Danger signs or symptoms of severe malaria\n* Anaemia (defined as Hb \\\u003C8g\u002Fdl)\n* Pregnant or lactating females\n* Regular use of drugs with haemolytic potential\n* Known hypersensitivity to any of the study drugs.",{"count":70,"type":19},1090,[72],"PHASE3","The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. The main question\\[s\\] it aims to answer are:\n\n* is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg\u002Fkg) non-inferior to high dose primaquine (7mg\u002Fkg over 7 days)\n* is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg\u002Fkg) superior to fixed dose tafenoquine (300mg)\n* is the tolerability and safety of TQRevised acceptable\n* is TQRevised acceptable and feasible Participants will receive a tafenoquine target dose 7.5mg\u002Fkg in weight bands. Researchers will compare this to patients receiving a fixed dose tafenoquine and high dose primaquine to see if safe and effective.",[25],"2025-07-15",{"date":77,"type":30},"2025-07-18",{"date":79,"type":30},"2024-05-10",{"date":81,"type":19},"2027-03-01",{"name":36,"class":37},""]